Stereotactic radiosurgery (SRS) alone versus whole brain radiotherapy plus SRS in patients with 1 to 4 brain metastases from non-small cell lung cancer stratified by the graded prognostic assessment: A meta-analysis (PRISMA) of randomized control trials

被引:12
|
作者
Qie, Shuai [1 ]
Li, Yanhong [1 ]
Shi, Hong-yun [1 ]
Yuan, Lanhui [1 ]
Su, Lei [1 ]
Zhang, Xi [1 ]
机构
[1] Hebei Univ, Affiliated Hosp, Dept Radiat Oncol, Baoding 071000, Hebei, Peoples R China
关键词
brain metastases; graded prognostic assessment; meta-analysis; stereotactic radiosurgery; whole brain radiotherapy; SECONDARY ANALYSIS; IMPACT;
D O I
10.1097/MD.0000000000011777
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background:The present study aims to assess the therapeutic effect of whole brain radiotherapy (WBRT) for brain metastases from non-small cell lung cancer stratified by graded prognostic assessment (GPA) through meta-analysis.Methods:The Cochrane Library, PubMed, Ovid (Elsevier) were retrieved. The included randomized controlled trials (RCT) were evaluated, and the statistical analysis was performed using RevMan 5.3 software. Cochrane handbook was applied to evaluate the methodological quality. Statistical significance was considered as P<.05.Results:There were 2 randomized control trials identified eligible for the meta-analysis. Stereotactic radiosurgery (SRS)+WBRT did not significantly improved overall survival (OS) in 2 subgroups. (GPA <2: HR, 0.93; 95% confidence interval [CI], 0.61-1.40; P=.71), (GPA 2: HR, 1.28; 95% CI, 0.58-2.80; P=.54). The use of SRS+WBRT significantly extended brain tumor recurrence (BTR) free time in both subgroups (GPA <2: HR, 5.46; 95% CI: 2.09-14.22; P=.0005), (GPA 2: HR, 4.24; 95% CI: 2.24-8.04; P<.00001). The meta-analysis showed salvage therapy was more frequent among the SRS-alone in 2 subgroups (GPA <2: RR, 5.83; 95% CI: 1.47-23.06; P=.01), (GPA 2: RR, 2.53; 95% CI: 1.30-4.93; P=.006). The rate of grade 3 or 4 late radiation toxic effects was similar in 2 subgroups between SRS and SRS+WBRTConclusions:Because there are few studies to meet inclusion criteria, we cannot include more researches. The results of this analysis must be carefully interpreted in view of the unclear risk of bias in inclusion in the study. This meta-analysis of 2 randomized trails indicated that the combined treatment group did not show a survival benefit over SRS alone. However, SRS+WBRT improved BTR free time in the subgroup both GPA <2 and GPA 2 with the similar grade 3 or 4 late radiation toxicities.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Outcomes in Patients Treated With Whole-Brain Radiation Therapy Versus Stereotactic Radiosurgery for Brain Metastases Secondary to Non-Small Cell Lung Cancer
    Henson, C.
    Arain, A.
    Herman, T.
    Ahmad, S.
    Matthiesen, C. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S693 - S693
  • [32] Meta-analysis of whole-brain radiotherapy plus temozolomide compared with whole-brain radiotherapy for the treatment of brain metastases from non-small-cell lung cancer
    Xin, Yong
    Guo, WenWen
    Yang, Chun Sheng
    Huang, Qian
    Zhang, Pei
    Zhang, Long Zhen
    Jiang, Guan
    CANCER MEDICINE, 2018, 7 (04): : 981 - 990
  • [33] The effect of non-small cell lung cancer histology on survival as measured by the graded prognostic assessment in patients with brain metastases treated by hypofractionated stereotactic radiotherapy
    Ma, Liang-Hua
    Li, Guang
    Zhang, Hong-Wei
    Wang, Zhi-Yu
    Dang, Jun
    Zhang, Shuo
    Yao, Lei
    RADIATION ONCOLOGY, 2016, 11
  • [34] The effect of non-small cell lung cancer histology on survival as measured by the graded prognostic assessment in patients with brain metastases treated by hypofractionated stereotactic radiotherapy
    Liang-Hua Ma
    Guang Li
    Hong-Wei Zhang
    Zhi-Yu Wang
    Jun Dang
    Shuo Zhang
    Lei Yao
    Radiation Oncology, 11
  • [35] RTOG 0320:A phase Ill trial comparing whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) alone versus WBRT with temozolomide (TMZ) or erlotinib for non-small cell lung cancer (NSCLC) and 1-3 brain metastases
    Sperduto, Paul W.
    Wang, Meihua
    Robins, H. Ian
    Schell, Michael C.
    Werner-Wasik, Maria
    Komaki, Ritsuko U.
    Souhami, Luis
    Buyyounouski, Mark K.
    Khuntia, Deepak
    Demas, William F.
    Shah, Sunjay A.
    Nedzi, Lucien A.
    Perry, G. A.
    Suh, John H.
    Mehta, Minesh P.
    CANCER RESEARCH, 2012, 72
  • [36] Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?
    Kim, Kyoung Ha
    Lee, Jeeyun
    Lee, Jung-Il
    Nam, Do Hyun
    Kong, Doo-Sik
    Ahn, Yong Chan
    Park, Hee Chul
    Kwon, O. Jung
    Kim, Hojoong
    Chang, Myung Hee
    Yi, Seong Yoon
    Ji, Sang Hoon
    Park, Yeon Hee
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    LUNG CANCER, 2010, 68 (02) : 258 - 263
  • [37] Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?
    Kim, Kyoung Ha
    Lee, Jeeyun
    Park, Yeon Hee
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myoung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S544 - S544
  • [38] Response and safety of whole-brain radiotherapy plus temozolomide for patients with brain metastases of non-small-cell lung cancer: A meta-analysis
    Han, Jianguo
    Qiu, Ming
    Su, Li
    Wu, Chong
    Cheng, Si
    Zhao, Zhijun
    Li, Danxia
    Wang, Menghui
    Tao, Wei
    Du, Shiwei
    THORACIC CANCER, 2021, 12 (23) : 3177 - 3183
  • [39] S-1 plus cisplatin with concurrent radiotherapy for stage III non-small cell lung cancer A meta-analysis (PRISMA) of randomized control trials
    Qie, Shuai
    Li, Yanhong
    Shi, Hong-yun
    Yuan, Lanhui
    Zhang, Xi
    MEDICINE, 2018, 97 (50)
  • [40] CyberKnife-based stereotactic radiosurgery or fractionated stereotactic radiotherapy in older patients with brain metastases from non-small cell lung cancer
    Lee, Jeongshim
    Kim, Hun Jung
    Kim, Woo Chul
    RADIATION ONCOLOGY JOURNAL, 2023, 41 (04): : 258 - 266